ES2058561T3 - Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa. - Google Patents

Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa.

Info

Publication number
ES2058561T3
ES2058561T3 ES89313264T ES89313264T ES2058561T3 ES 2058561 T3 ES2058561 T3 ES 2058561T3 ES 89313264 T ES89313264 T ES 89313264T ES 89313264 T ES89313264 T ES 89313264T ES 2058561 T3 ES2058561 T3 ES 2058561T3
Authority
ES
Spain
Prior art keywords
reductase
inhibitors
5alpha
steroid
phosphonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89313264T
Other languages
English (en)
Inventor
Dennis Alan Holt
Mark Alan Levy
Brian Walter Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2058561T3 publication Critical patent/ES2058561T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPONENTES DE ESTRUCTURA (I) EN EL QUE LAS LINEAS DOTADAS INDICAN LA PRESENCIA OPCIONAL DE ENLACES DOBLES E INTER ALIA Z ES (CH2)N DONDE N ES 0-2, R ES H, HIDROXI O ACETOXI, R1 ES H O AUSENTE Y R2 ESTA AUSENTE, H O CH3; PROCESOS PARA SU PREPARACION, COMPOSICIONES QUE LOS CONTIENEN Y SU USO EN MEDICINA COMO INHIBIDORES DE REDUCTASA-A-5.
ES89313264T 1988-12-23 1989-12-19 Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa. Expired - Lifetime ES2058561T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/290,211 US4946834A (en) 1988-12-23 1988-12-23 Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2058561T3 true ES2058561T3 (es) 1994-11-01

Family

ID=23114990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89313264T Expired - Lifetime ES2058561T3 (es) 1988-12-23 1989-12-19 Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa.

Country Status (12)

Country Link
US (1) US4946834A (es)
EP (1) EP0375351B1 (es)
JP (1) JPH02215795A (es)
AT (1) ATE110736T1 (es)
AU (1) AU631387B2 (es)
CA (1) CA2005165A1 (es)
DE (1) DE68917885T2 (es)
DK (1) DK645289A (es)
ES (1) ES2058561T3 (es)
IE (1) IE65517B1 (es)
PT (1) PT92722A (es)
ZA (1) ZA899670B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4970204A (en) * 1989-08-23 1990-11-13 Smithkline Beecham Corporation 3-substituted nitro-steroid derivatives as 5-α-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
IL104601A0 (en) * 1992-02-07 1993-07-08 Smithkline Beecham Corp Process for the preparation of steroidal dienes
ES2105108T3 (es) * 1992-04-20 1997-10-16 Sankyo Co Esteroides para el tratamiento de la hipertrofia prostatica, su preparacion y su utilizacion.
EP0641211A1 (en) * 1992-05-21 1995-03-08 Endorecherche Inc. INHIBITORS OF TESTOSTERONE 5$g(a)-REDUCTASE ACTIVITY
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
EP0754701B1 (en) * 1994-04-04 1998-08-12 Meiji Milk Products Company Limited Novel progesterone compound and use thereof
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
JP2000309599A (ja) 1999-04-13 2000-11-07 Kyowa Hakko Kogyo Co Ltd エストラ−１，３，５（１０），１６−テトラエン誘導体
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
HUE059078T2 (hu) 2009-02-20 2022-10-28 Enhanx Biopharm Inc Glutation-alapú hatóanyagszállító rendszer
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
DK465481A (da) * 1980-11-21 1982-05-22 Hoffmann La Roche Fremgangsmaade til fremstilling af d-homostemoider
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
CA2005165A1 (en) 1990-06-23
AU4700389A (en) 1990-06-28
DK645289A (da) 1990-06-24
IE894110L (en) 1990-06-23
US4946834A (en) 1990-08-07
ATE110736T1 (de) 1994-09-15
ZA899670B (en) 1990-11-28
DK645289D0 (da) 1989-12-19
IE65517B1 (en) 1995-11-01
AU631387B2 (en) 1992-11-26
JPH02215795A (ja) 1990-08-28
PT92722A (pt) 1990-06-29
DE68917885T2 (de) 1994-12-22
EP0375351B1 (en) 1994-08-31
EP0375351A1 (en) 1990-06-27
DE68917885D1 (de) 1994-10-06

Similar Documents

Publication Publication Date Title
ZA899671B (en) Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
ES2058561T3 (es) Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa.
ES2067557T3 (es) Esteroides aromaticos sustituidos con acido fosfinico como inhibidores de la esteroide 5-d-reductasa.
ES2065400T3 (es) Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa.
NO905608L (no) Fremgangsmaate for fremstilling av a-nor-steroid-3-karboksylsyrederivater.
PT86652A (pt) Steroid 5-alpha-reductase inhibitors
ZA899669B (en) Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-alpha-reductase
FR2521995B1 (es)
ATE90355T1 (de) Weiche steroide mit anti-entzuendungswirkung.
ATE73136T1 (de) Verfahren zur herstellung von 6alpha, 9alphadifluor-11beta, 17alpha-dihydroxy-16alpha-methyl4-pregnen-3,20-dion und dessen derivate.
ES2018874B3 (es) Derivado taurine, su preparacion y composiciones farmaceuticas que lo contiene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 375351

Country of ref document: ES